USP <1117> "Microbial Best Laboratory Practices": An Interview with Scott Sutton - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP <1117> "Microbial Best Laboratory Practices": An Interview with Scott Sutton
Scott Sutton discusses the current state of USP 91117: and USP's plans for future revisions.


Pharmaceutical Technology


US Pharmacopeia's General Information Chapter ‹1117› "Microbiological Best Laboratory Practices" is currently under revision after being in effect since 2006. It currently stands as the only guidance document that covers the basics of running a microbiological laboratory in the pharmaceutical industry. Scott Sutton is on USP's Committee of Experts, Microbiology and Sterility Assurance, and spoke to Pharmaceutical Technology regarding the recent developments in this chapter.

PharmTech: Can you provide a brief background into the state of the industry that led USP into thinking a chapter on microbiology laboratories was necessary?

Sutton: We had been talking about a chapter on microbiology laboratory practices since the 1990s. USP would get regular requests from laboratories for clarification on how you should be performing certain activities, some of these activities very basic to the laboratory functions. There was also a lot of interest in how to perform investigations and what is the best way to do a variety of standard operations. It was pretty clear that the people that were functioning as managers and supervisors and were heading-up the laboratory were asking very basic questions about how to perform microbiological testing. There were just not enough, and still aren't, microbiologists to go around.

PharmTech: Which types of companies were asking these questions?

Sutton: Smaller companies in particular were asking for a lot more clarification in terms of a USP informational chapter. On the other hand, however, the larger companies were less enthusiastic about additional USP guidance on this topic. For them, fewer regulations were better, which was an entirely understandable position. But that still left most laboratories searching for answers and unsure of their practices during regulatory audits. Also, as a historical perspective, at the same time these discussions were going on, there was a big push to harmonize sterility test and the antimicrobial efficacy test. It was obvious that it was going to be a wasted effort if once these tests went out, laboratories employed questionable procedures.

PharmTech: Once the decision was made to get started on the chapter, what was the approach?

Sutton: We talked about the chapter for years as an interesting idea before actually trying to publish it, and circulated several versions of a potential chapter among the committee before publication. Within the committee there was significant concern about the issue of being too proscriptive while at the same time being relevant and "informational." The result was what is admittedly a vague description of guiding principles for how you should run a quality control microbiology lab. We published this as the first draft of the proposed new informational chapter (see Pharmaceutical Forum (PF) 29 (3), 842 [2003]). It originally was released under the title of "good laboratory practices for microbiology." But because of input from the agency, we amended the title to the current one and incorporated several comments from the field (see PF 30 (5), 1713 [2004]).

For example, some of the comments said media was not important, and that we should consider dropping the media section of the chapter. But that is wrong. Media is critical in a microbiology laboratory but this point was apparently not coming across in the original and so the text was amended to try to clarify this. Other comments pointed out potential improvements in the chapter and were incorporated. The point of the chapter was to focus people's attention on those aspects important to running a well-controlled microbiology lab in a controlled manner, including media, culture, training, cleanliness, hygiene, and equipment. And for that purpose, it has been an extremely successful chapter.

PharmTech: What has been the response to this chapter?

Sutton: The official chapter first appeared in USP's Supplement 2, in 2006. The response has been generally very positive, although it has been interesting to see how people are applying it. For example, the PMFList (pharmaceutical microbiology forum) is an active online discussion group devoted to QC microbiology. Different aspects of this chapter are regularly debated in this forum, and in fact some of these discussions directly influenced changes in the chapter to be proposed in the upcoming proposed revisions to the chapter (due out in the March-April 2009 PF).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here